PMC:7696151 / 18612-23009
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 520 | 56-73 | Species | denotes | Chikungunya virus | Tax:37124 |
| 521 | 216-222 | Species | denotes | humans | Tax:9606 |
| 522 | 239-255 | Species | denotes | Aedes albopictus | Tax:7160 |
| 523 | 260-273 | Species | denotes | Aedes aegypti | Tax:7159 |
| 524 | 75-80 | Species | denotes | CHIKV | Tax:37124 |
| 525 | 183-188 | Species | denotes | CHIKV | Tax:37124 |
| 526 | 1021-1024 | Chemical | denotes | HCQ | MESH:D006886 |
| 527 | 1057-1069 | Chemical | denotes | methotrexate | MESH:D008727 |
| 528 | 1071-1074 | Chemical | denotes | MTX | MESH:D008727 |
| 529 | 1083-1096 | Chemical | denotes | sulfasalazine | MESH:D012460 |
| 530 | 227-235 | Disease | denotes | infected | MESH:D007239 |
| 531 | 435-448 | Disease | denotes | polyarthritis | MESH:D001168 |
| 532 | 450-455 | Disease | denotes | fever | MESH:D005334 |
| 533 | 463-467 | Disease | denotes | rash | MESH:D005076 |
| 534 | 545-554 | Disease | denotes | arthritis | MESH:D001168 |
| 535 | 603-615 | Disease | denotes | inflammation | MESH:D007249 |
| 536 | 617-627 | Disease | denotes | neuropathy | MESH:D009422 |
| 537 | 629-655 | Disease | denotes | neuropsychiatric disorders | MESH:D001523 |
| 538 | 661-690 | Disease | denotes | peripheral vascular disorders | MESH:D016491 |
| 539 | 879-895 | Disease | denotes | CHIKV infections | MESH:D007239 |
| 559 | 1339-1347 | Species | denotes | patients | Tax:9606 |
| 560 | 1361-1366 | Species | denotes | CHIKV | Tax:37124 |
| 561 | 1119-1122 | Chemical | denotes | HCQ | MESH:D006886 |
| 562 | 1294-1297 | Chemical | denotes | HCQ | MESH:D006886 |
| 563 | 1450-1461 | Chemical | denotes | aceclofenac | MESH:C056498 |
| 564 | 1463-1466 | Chemical | denotes | ACF | MESH:C056498 |
| 565 | 1480-1483 | Chemical | denotes | HCQ | MESH:D006886 |
| 566 | 1499-1511 | Chemical | denotes | prednisolone | MESH:D011239 |
| 567 | 1513-1516 | Chemical | denotes | PRD | MESH:D011239 |
| 568 | 1629-1632 | Chemical | denotes | HCQ | MESH:D006886 |
| 569 | 1939-1942 | Chemical | denotes | ACF | MESH:C056498 |
| 570 | 1945-1948 | Chemical | denotes | HCQ | MESH:D006886 |
| 571 | 1953-1956 | Chemical | denotes | ACF | MESH:C056498 |
| 572 | 1994-1997 | Chemical | denotes | ACF | MESH:C056498 |
| 573 | 2000-2003 | Chemical | denotes | HCQ | MESH:D006886 |
| 574 | 2050-2053 | Chemical | denotes | ACF | MESH:C056498 |
| 575 | 1170-1179 | Disease | denotes | infection | MESH:D007239 |
| 576 | 1671-1686 | Disease | denotes | CHIKV infection | MESH:D007239 |
| 577 | 1734-1738 | Disease | denotes | pain | MESH:D010146 |
| 612 | 2219-2227 | Species | denotes | patients | Tax:9606 |
| 613 | 2476-2484 | Species | denotes | patients | Tax:9606 |
| 614 | 2649-2657 | Species | denotes | patients | Tax:9606 |
| 615 | 2973-2981 | Species | denotes | patients | Tax:9606 |
| 616 | 3198-3206 | Species | denotes | patients | Tax:9606 |
| 617 | 3663-3671 | Species | denotes | patients | Tax:9606 |
| 618 | 3006-3017 | Species | denotes | chikungunya | Tax:37124 |
| 619 | 2118-2123 | Species | denotes | CHIKV | Tax:37124 |
| 620 | 2268-2273 | Species | denotes | CHIKV | Tax:37124 |
| 621 | 2079-2082 | Chemical | denotes | HCQ | MESH:D006886 |
| 622 | 2195-2198 | Chemical | denotes | HCQ | MESH:D006886 |
| 623 | 2728-2731 | Chemical | denotes | HCQ | MESH:D006886 |
| 624 | 2752-2755 | Chemical | denotes | MXT | MESH:D008727 |
| 625 | 2760-2773 | Chemical | denotes | sulfasalazine | MESH:D012460 |
| 626 | 2893-2896 | Chemical | denotes | HCQ | MESH:D006886 |
| 627 | 2932-2935 | Chemical | denotes | MTX | MESH:D008727 |
| 628 | 2940-2953 | Chemical | denotes | sulfasalazine | MESH:D012460 |
| 629 | 3055-3058 | Chemical | denotes | HCQ | MESH:D006886 |
| 630 | 3127-3130 | Chemical | denotes | MTX | MESH:D008727 |
| 631 | 3140-3153 | Chemical | denotes | sulfasalazine | MESH:D012460 |
| 632 | 3170-3173 | Chemical | denotes | HCQ | MESH:D006886 |
| 633 | 3310-3320 | Chemical | denotes | prednisone | MESH:D011241 |
| 634 | 3587-3590 | Chemical | denotes | MTX | MESH:D008727 |
| 635 | 3613-3616 | Chemical | denotes | HCQ | MESH:D006886 |
| 636 | 2378-2384 | Disease | denotes | nausea | MESH:D009325 |
| 637 | 2386-2396 | Disease | denotes | stomatitis | MESH:D013280 |
| 638 | 2398-2402 | Disease | denotes | rash | MESH:D005076 |
| 639 | 2404-2412 | Disease | denotes | headache | MESH:D006261 |
| 640 | 2437-2450 | Disease | denotes | CHIKV disease | MESH:D003141 |
| 641 | 2531-2540 | Disease | denotes | synovitis | MESH:D013585 |
| 642 | 3018-3027 | Disease | denotes | arthritis | MESH:D001168 |
| 643 | 3447-3451 | Disease | denotes | pain | MESH:D010146 |
| 644 | 3648-3662 | Disease | denotes | CHIKV infected | MESH:D007239 |
| 645 | 3701-3714 | Disease | denotes | polyarthritis | MESH:D001168 |
| 655 | 4081-4092 | Species | denotes | chikungunya | Tax:37124 |
| 656 | 4218-4221 | Chemical | denotes | HCQ | MESH:D006886 |
| 657 | 3800-3815 | Disease | denotes | virus infection | MESH:D001102 |
| 658 | 3866-3882 | Disease | denotes | CHIKV infections | MESH:D007239 |
| 659 | 3912-3919 | Disease | denotes | viremia | MESH:D014766 |
| 660 | 4093-4102 | Disease | denotes | arthritis | MESH:D001168 |
| 661 | 4238-4255 | Disease | denotes | viremia reduction | MESH:D007022 |
| 662 | 4319-4328 | Disease | denotes | infection | MESH:D007239 |
| 663 | 4384-4396 | Disease | denotes | inflammation | MESH:D007249 |
LitCovid-PD-HP
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T11 | 450-455 | Phenotype | denotes | fever | http://purl.obolibrary.org/obo/HP_0001945 |
| T12 | 463-467 | Phenotype | denotes | rash | http://purl.obolibrary.org/obo/HP_0000988 |
| T13 | 545-554 | Phenotype | denotes | arthritis | http://purl.obolibrary.org/obo/HP_0001369 |
| T14 | 617-627 | Phenotype | denotes | neuropathy | http://purl.obolibrary.org/obo/HP_0009830 |
| T15 | 1734-1738 | Phenotype | denotes | pain | http://purl.obolibrary.org/obo/HP_0012531 |
| T16 | 2378-2384 | Phenotype | denotes | nausea | http://purl.obolibrary.org/obo/HP_0002018 |
| T17 | 2386-2396 | Phenotype | denotes | stomatitis | http://purl.obolibrary.org/obo/HP_0010280 |
| T18 | 2398-2402 | Phenotype | denotes | rash | http://purl.obolibrary.org/obo/HP_0000988 |
| T19 | 2404-2412 | Phenotype | denotes | headache | http://purl.obolibrary.org/obo/HP_0002315 |
| T20 | 2531-2540 | Phenotype | denotes | synovitis | http://purl.obolibrary.org/obo/HP_0100769 |
| T21 | 3018-3027 | Phenotype | denotes | arthritis | http://purl.obolibrary.org/obo/HP_0001369 |
| T22 | 3447-3451 | Phenotype | denotes | pain | http://purl.obolibrary.org/obo/HP_0012531 |
| T23 | 3912-3919 | Phenotype | denotes | viremia | http://purl.obolibrary.org/obo/HP_0020071 |
| T24 | 4093-4102 | Phenotype | denotes | arthritis | http://purl.obolibrary.org/obo/HP_0001369 |
| T25 | 4238-4245 | Phenotype | denotes | viremia | http://purl.obolibrary.org/obo/HP_0020071 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T134 | 0-6 | Sentence | denotes | 2.2.2. |
| T135 | 7-24 | Sentence | denotes | Chikungunya Virus |
| T136 | 25-172 | Sentence | denotes | The single-stranded RNA virus, Chikungunya virus (CHIKV), is an alphavirus belonging to the Togaviridae family, spread mainly in America’s regions. |
| T137 | 173-293 | Sentence | denotes | The usual CHIKV vectors are rodents, while humans are infected by Aedes albopictus and Aedes aegypti and mosquito bites. |
| T138 | 294-848 | Sentence | denotes | The first incubation stage can vary between 2 and 12 days, and three phases follow it: (1) the acute viraemic phase, characterized by severe polyarthritis, fever, and a rash, generally resolving in three weeks; (2) the post-acute stage, identified by arthritis with the addition of synovial and periarticular inflammation, neuropathy, neuropsychiatric disorders, and peripheral vascular disorders, usually takes its time at the end of three months; (3) the chronic phase that appears when the symptoms of the previous phase do not end after three months. |
| T139 | 849-1118 | Sentence | denotes | Generally, the acute phase of CHIKV infections is treated with non-steroidal anti-inflammatory drugs (NSAIDs), while for the chronic persistent phase, treatments involving HCQ as monotherapy or combined with methotrexate (MTX) and/or sulfasalazine seem to be effective. |
| T140 | 1119-1254 | Sentence | denotes | HCQ does not appear to affect the initial stage of infection, as demonstrated in a prospective randomized parallel-group study of 2009. |
| T141 | 1255-1376 | Sentence | denotes | In this trial, combinations of NSAIDs, HCQ, and/or corticosteroids were assessed in patients with classic CHIKV features. |
| T142 | 1377-1544 | Sentence | denotes | A total of 120 subjects were divided into groups treated with 200 mg/day aceclofenac (ACF), 400 mg/day HCQ, and 10 mg/day prednisolone (PRD) in different combinations. |
| T143 | 1545-1611 | Sentence | denotes | Only 114 subjects remained until the end of the trial (six weeks). |
| T144 | 1612-1877 | Sentence | denotes | It was seen that HCQ had no benefit in the early stages of CHIKV infection and also in the reduction of the VAS (used for pain assessment) and in the improvement of Barthel’s indexes (used for instrumental activities of daily living and activities of daily living). |
| T145 | 1878-1963 | Sentence | denotes | In fact, there was no difference between groups treated with ACF + HCQ and ACF alone. |
| T146 | 1964-2065 | Sentence | denotes | Similarly, the combination of ACF + HCQ + PRD did not add any additional benefit over ACF + PRD [26]. |
| T147 | 2066-2147 | Sentence | denotes | In contrast, HCQ seems to affect the improvement of CHIKV chronic phase diseases. |
| T148 | 2148-2288 | Sentence | denotes | In a recent multicenter study, the efficacy of HCQ was evaluated in 39 patients with rheumatic manifestation related to CHIKV chronic phase. |
| T149 | 2289-2485 | Sentence | denotes | In four subjects, the treatment was interrupted due to the onset of side effects such as nausea, stomatitis, rash, headache, while the evolution of CHIKV disease was evaluated in only 22 patients. |
| T150 | 2486-2671 | Sentence | denotes | After three months of treatment, evidence of synovitis was disappeared in 10 of 20 subjects (50%) with swollen joins while complete remission was verified in five patients (19.2%) [27]. |
| T151 | 2672-2818 | Sentence | denotes | However, another study demonstrated that the effects of HCQ in combination with MXT and sulfasalazine were superior to those shown in monotherapy. |
| T152 | 2819-3028 | Sentence | denotes | In particular, in a randomized controlled open-label study, the impact of HCQ in monotherapy or association with MTX and sulfasalazine was assessed in 72 patients with chronic persistent chikungunya arthritis. |
| T153 | 3029-3207 | Sentence | denotes | In this trial, 400 mg/day HCQ were administrated to 35 subjects, while a combination of 15 mg/day MTX, 1 g/day sulfasalazine, and 400 mg/day HCQ was administrated to 37 patients. |
| T154 | 3208-3334 | Sentence | denotes | Either treatment lasted 24 weeks and for the first 6 weeks, both groups received an escalated dose of prednisone (7.5 mg/day). |
| T155 | 3335-3457 | Sentence | denotes | At the end of the 24th week, only the combination of drugs improved disease activity and reduced disability and pain [28]. |
| T156 | 3458-3720 | Sentence | denotes | These results, following those obtained in a previous uncontrolled 16-week study, since a reduction in ACR score was shown after MTX (15–20 mg/weekly) and HCQ (400 mg/day) administration to CHIKV infected patients with persistent inflammatory polyarthritis [29]. |
| T157 | 3721-3823 | Sentence | denotes | The results obtained could be explained with the different characterization of virus infection phases. |
| T158 | 3824-4108 | Sentence | denotes | It is known that while the acute phase of CHIKV infections is due to the development of viremia, the chronic phase is closely related to an immune-mediated phenomenon, as pro-inflammatory cytokines and chemokines play important roles in the pathogenesis of chikungunya arthritis [44]. |
| T159 | 4109-4397 | Sentence | denotes | Therefore, considering the results obtained from these clinical studies, it is possible to say that although HCQ does not affect viremia reduction, as demonstrated by the lack of activity in the first phase of infection, it can improve the chronic phase diseases by reducing inflammation. |